Schizophrenia

...ba href=/schizophrenia/a/b, the report in human biology on 'Live Science' said.

1 Sitemap Copyright ©2006Times Internet Limited.

All rights reserved.

For reprint rights: Times Syndication Service ...

...ba href=/schizophrenia/a/b, the report in human biology on 'Live Science' said.

The electronic olfactory system, which looks nothing like a nose, will be made up of sensors similar to receptors in our nasal passages.

These sensors will be triggered by molecules floating in the air.

When a patient breathes into the device, different molecules will trigger a different set of sensors to light up.

Bright and his research team can train the device, which is made of artificial neurons mimicking a brain, to connect the patterns of lights with particular diseases.

Scientists will start training by comparing the samples of patients already diagnosed with cancer.

They will search for similar patterns in the patients' breath so that in the future when the device sees those patterns, it recognises cancer.

So far, Bright's team has engineered about a 100 different sensors, which match up to all kinds of molecules.

Their goal is to produce a million.

Sci.

& Tech.

Cities Delhi Kolkata Sections: Top Stories Home Copyright © 2006, The Hindu.

Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hind...

...ba href=/schizophrenia/a/b and acute mania in bipolar disorder which we are developing with Pfizer, is progressing according to plan,” he said.

“The clinical program is due to be completed by the end of the year, while filing with the FDA in the United States is expected early in 2007.

We also expect to submit the file for sugammadex-a reversal agent used during general anesthesia-during the first half of next year.” Herm Cukier, Organon’s Executive Vice President of Global Marketing, went on to inform analysts that the company’s new fertility product (Org 36286), is planned for submission in 2008, with a new contraceptive (NOMAC/E2) expected to be filed in 2009 and an insomnia treatment (Org 50081) expected to be submitted in 2010.

Building on biotechnology and neuroscience Looking in more detail at human healthcare, analysts heard that the business will not only work to sustain leadership status in its traditional areas of gynecology (eg NuvaRing® and Livial®); fertility (Puregon Pen®/Follistim Pen®); and anesthesia (Esmeron®/Zemuron®); but will also focus on rebuilding its position in neuroscience.

“Our core indication areas provide a solid base with selected opportunities for growth, while in the medium and long-term, neuroscience provides us with interesting growth opportunities,” explained Organon’s Executive Vice President of Research and Development, David Nicholson.

“We are also building a biotechnology franchise as an additio...